S

J

SCOAZEC , J.-Y.

Last name: SCOAZEC

First name: J.-Y.

March 29, 2012 (v1)

Journal article

Metadata-only

Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines.

Grepin, R. Guyot, M. Jacquin, M.

The anti-VEGF targeted antibody bevacizumab (BVZ) has been approved for treating renal cell carcinomas (RCCs). Although BVZ increases the progression-free survival of patients with metastatic RCC, the effect on overall survival is poor. To gain insight into the limited efficacy of BVZ on overall survival, we analyzed patient samples of RCC for...

Uploaded on: December 4, 2022